SRR613474
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.426
- APICAL_SURFACE+0.334
- KRAS_SIGNALING_DN+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- PANCREAS_BETA_CELLS+0.299
- UV_RESPONSE_DN+0.298
- APICAL_JUNCTION+0.275
- ANGIOGENESIS+0.271
- ESTROGEN_RESPONSE_EARLY+0.264
- KRAS_SIGNALING_UP+0.240
Top 10 suppressed
- MYC_TARGETS_V1-0.475
- MYC_TARGETS_V2-0.468
- DNA_REPAIR-0.465
- NOTCH_SIGNALING-0.460
- INTERFERON_ALPHA_RESPONSE-0.411
- E2F_TARGETS-0.401
- UNFOLDED_PROTEIN_RESPONSE-0.392
- G2M_CHECKPOINT-0.364
- INTERFERON_GAMMA_RESPONSE-0.282
- WNT_BETA_CATENIN_SIGNALING-0.253
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR615213 | GTEX | — | 0.910 |
| 2 | SRR614742 | GTEX | — | 0.902 |
| 3 | SRR656552 | GTEX | — | 0.888 |
| 4 | SRR661133 | GTEX | — | 0.888 |
| 5 | SRR614814 | GTEX | — | 0.876 |
| 6 | SRR599448 | GTEX | — | 0.875 |
| 7 | SRR604262 | GTEX | — | 0.866 |
| 8 | SRR662007 | GTEX | — | 0.865 |
| 9 | SRR612563 | GTEX | — | 0.858 |
| 10 | SRR1336292 | GTEX | — | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.426 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.334 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.299 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.298 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.275 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.271 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.264 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.225 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.223 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.203 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.192 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.166 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.134 | Temsirolimus | — uncovered |
| COAGULATION | 0.098 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.097 | Idelalisib | — uncovered |
| HYPOXIA | 0.057 | Idelalisib | — uncovered |
| COMPLEMENT | 0.038 | Inavolisib | — uncovered |